drugset / Trial / NCT05303272
A Study to Evaluate Efficacy and Safety of Abatacept in Participants of Pemphigus Vulgaris (PV)
Phase 4
Unknown
60 enrolled
Tongji Hospital
Wuhan Central Hospital · collabWuhan Hospital of Traditional Chinese Medicine · collab
RandomizedCrossoverDouble-blindTreatment
Summary
Pemphigus vulgaris (PV) is a rare, chronic, debilitating, and potentially life-threatening autoimmune disorder that is characterized by mucocutaneous blisters.Abatacept is a biologic drug that belongs to the class of T-cell co-stimulation modulators and is used for the treatment of autoimmune diseases.
Timeline
- Start
- 2021-02-01
- Primary completion
- 2022-09-01
- Completion
- 2022-09-30
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Abatacept | Other / unclassified | 125 mg | Subcutaneous |
| Subject | Abatacept | Other / unclassified | 150 mg | Subcutaneous |
| Comparator | Mycophenolate Mofetil | Small molecule | 500 mg | — |
| Comparator | Mycophenolate Mofetil | Small molecule | 1000 mg | — |